Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
149 hedge funds and large institutions have $884M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 34 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
26% more capital invested
Capital invested by funds: $704M → $884M (+$180M)
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
1% less funds holding
Funds holding: 151 → 149 (-2)
20% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 50
70% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $70.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$58.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$44.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$36.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$17.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$66M |
| 2 |
Goldman Sachs
New York
|
-$31.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12M |
| 4 |
Millennium Management
New York
|
-$11M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$10.3M |
RETA Hedge Fund Activity: Q1 2022 in Review
149 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2022, worth a combined $884M — up 26% from $704M a quarter earlier.
Fund positioning in RETA was balanced in Q1 2022: 34 funds opened new positions, 34 closed out, 40 added to existing stakes and 50 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $58.6M. The largest seller was Invesco, cutting an estimated $66M.
- 149 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2022, down from 151 in Q4 2021.
- Funds reported $884M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2022, up 26% quarter-over-quarter.
- 34 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2022 and 34 closed out, a net change of 0 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2022 was EcoR1 Capital, an estimated $58.6M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2022 was Invesco, an estimated $66M sold.
Based on aggregated 13F filings for Q1 2022.